Total Payments
$430.36
2023 Payments
$13.89
Companies
5
Transactions
23
Medicare Patients
1,020
Medicare Billing
$171,978
Payment Breakdown by Category
Food & Beverage$416.47 (96.8%)
Education$13.89 (3.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $416.47 | 22 | 96.8% |
| Education | $13.89 | 1 | 3.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $180.54 | 11 | $0 (2019) |
| Allergan, Inc. | $144.20 | 7 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $73.38 | 3 | $0 (2019) |
| PFIZER INC. | $18.35 | 1 | $0 (2019) |
| Amgen Inc. | $13.89 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $13.89 | 1 | Amgen Inc. ($13.89) |
| 2020 | $19.67 | 1 | Allergan, Inc. ($19.67) |
| 2019 | $161.54 | 8 | Boehringer Ingelheim Pharmaceuticals, Inc. ($49.58) |
| 2018 | $142.85 | 7 | Allergan Inc. ($80.49) |
| 2017 | $92.41 | 6 | Merck Sharp & Dohme Corporation ($92.41) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/22/2023 | Amgen Inc. | — | Education | In-kind items and services | $13.89 | General |
| 04/07/2020 | Allergan, Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/30/2019 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $24.69 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/08/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/12/2019 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/11/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/25/2019 | PFIZER INC. | PREVNAR - 13 (Biological) | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: VACCINES | ||||||
| 07/24/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA (Drug) | Food and Beverage | In-kind items and services | $23.21 | General |
| Category: RESPIRATORY | ||||||
| 07/16/2019 | Merck Sharp & Dohme Corporation | PREVYMIS (Drug), DIFICID, ZINPLAVA | Food and Beverage | In-kind items and services | $12.88 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/21/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.37 | General |
| Category: DIABETES | ||||||
| 09/26/2018 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/25/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: RESPIRATORY | ||||||
| 06/04/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/23/2018 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/23/2018 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/19/2018 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/05/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/04/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/25/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/10/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/08/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/03/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $11.72 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/07/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 350 | 560 | $172,715 | $59,855 |
| 2022 | 7 | 305 | 553 | $171,570 | $55,580 |
| 2021 | 6 | 168 | 328 | $102,010 | $31,932 |
| 2020 | 5 | 197 | 306 | $102,926 | $24,611 |
Total Patients
1,020
Total Services
1,747
Medicare Billing
$171,978
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 62 | 130 | $31,605 | $12,775 | 40.4% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 49 | 49 | $32,290 | $10,614 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 48 | 77 | $32,915 | $10,538 | 32.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 64 | 68 | $30,695 | $9,703 | 31.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 52 | 117 | $19,680 | $7,745 | 39.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 68 | $20,850 | $6,359 | 30.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 26 | 51 | $4,680 | $2,122 | 45.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 74 | 152 | $40,660 | $13,061 | 32.1% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 54 | 54 | $38,580 | $12,360 | 32.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 54 | 58 | $29,555 | $9,638 | 32.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 35 | 53 | $22,275 | $7,874 | 35.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 39 | 106 | $19,250 | $6,335 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 23 | 38 | $11,670 | $3,296 | 28.2% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 26 | 92 | $9,580 | $3,016 | 31.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 47 | 50 | $28,750 | $8,483 | 29.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 24 | 38 | $15,770 | $5,979 | 37.9% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 50 minutes | Office | 2021 | 23 | 23 | $17,595 | $5,666 | 32.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 27 | 49 | $14,455 | $4,334 | 30.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 27 | 68 | $13,940 | $4,185 | 30.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 20 | 100 | $11,500 | $3,284 | 28.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 56 | 97 | $35,158 | $9,326 | 26.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 52 | 96 | $27,840 | $6,261 | 22.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 26 | 26 | $20,288 | $4,755 | 23.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 43 | 44 | $12,760 | $2,761 | 21.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 20 | 43 | $6,880 | $1,508 | 21.9% |
About Loren Greenberg, MS, MD
Loren Greenberg, MS, MD is a Geriatric Medicine healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730241357.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Loren Greenberg, MS, MD has received a total of $430.36 in payments from pharmaceutical and medical device companies, with $13.89 received in 2023. These payments were reported across 23 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($416.47).
As a Medicare-enrolled provider, Greenberg has provided services to 1,020 Medicare beneficiaries, totaling 1,747 services with total Medicare billing of $171,978. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Medicine
- Other Specialties Geriatric Medicine
- Location New Haven, CT
- Active Since 12/14/2006
- Last Updated 01/16/2024
- Taxonomy Code 207RG0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1730241357
Products in Payments
- ZERBAXA (Drug) $167.66
- TEFLARO (Drug) $80.73
- DALVANCE (Drug) $63.47
- JARDIANCE (Drug) $26.37
- SPIRIVA RESPIMAT (Drug) $23.80
- SPIRIVA (Drug) $23.21
- PREVNAR - 13 (Biological) $18.35
- PREVYMIS (Drug) $12.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Geriatric Medicine Doctors in New Haven
Dr. Susann Varano, Md, MD
Geriatric Medicine — Payments: $61,923
Geriatric Medicine $61,923
Henry Yaggi, Md, MD
Geriatric Medicine — Payments: $9,513
Geriatric Medicine $9,513
Thomas Gill, Md, MD
Geriatric Medicine — Payments: $2,693
Geriatric Medicine $2,693
Jesse Chua-Reyes, M.d, M.D
Geriatric Medicine — Payments: $674.24
Geriatric Medicine $674.24
Leen Bakkali, Md, MD
Geriatric Medicine — Payments: $264.84
Geriatric Medicine $264.84
Ronald Miller, M.d, M.D
Geriatric Medicine — Payments: $154.70
Geriatric Medicine $154.70